Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Oct 28, 2019 7:00 AM - Oct 30, 2019 12:30 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

DIA/FDA Oligonucleotide-Based Therapeutics Conference

Session 5 Track A: Clinical Experience with Lipid Nanoparticle- Based Delivery of Oligonucleotides

Session Chair(s)

Christine  Swenson

Christine Swenson

Head, Global Regulatory Affairs

Moderna Therapeutics, United States

Delivery of oligonucleotides using lipid nanoparticles (LNP) has been an emerging area of interest over the past decade. Clinical progress with LNP-mediated delivery of siRNAs, mRNAs, and saRNAs will be discussed.

Learning Objective :

At the conclusion of this session, participants should be able to:

  • Understand the use of LNP approaches for delivery of various oligonucleotides
  • Become familiar with clinical efficacy and safety using this modality for different diseases


Pushkal  Garg

Development and Approval of ONPATTRO, the First RNAi Therapeutic

Pushkal Garg

Alnylam Pharmaceuticals, Inc., United States

Christine  Swenson

Emerging Clinical Data for Intratumor and Systemic Administration of mRNA Therapies

Christine Swenson

Moderna Therapeutics, United States

Head, Global Regulatory Affairs

Nagy  Habib, MD, PhD

MTL-CEBPA, The First Small Activating RNA Therapy in Clinical Development

Nagy Habib, MD, PhD

MiNA Therapeutics Limited , United Kingdom

Head of Research and Development

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.